Day: March 25, 2026

LB-102 has potential to be the first benzamide approved for schizophrenia in the U.S. NOVA-2 trial to enroll approximately 460 patients Primary endpoint to evaluate change in PANSS total score at week 6; secondary endpoints to include evaluations of negative symptoms and cognitive performance as well as safety and tolerability Topline data expected in 2H 2027 NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) — LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia, bipolar depression, adjunctive major depressive disorder (MDD), and other neuropsychiatric diseases, today announced the initiation of its pivotal Phase 3 trial (NOVA-2) evaluating the efficacy and safety of LB-102 as a treatment for schizophrenia. LB-102, a novel, once-daily,...

Company Joins AASM Foundation Corporate Recognition Program and Sponsors Junior Investigator Research Grant as IHL-42X Advances Toward Potential Oral Treatment for Obstructive Sleep Apnea MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) — Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for high-impact indications, today announced it has entered into a Partnership Agreement with the American Academy of Sleep Medicine (AASM) Foundation. Through this partnership, Incannex has joined the AASM Foundation’s Corporate Recognition Program and will sponsor a Focused Projects Grant for Junior Investigators dedicated to the Diagnosis, Management, and Treatment of Sleep Apnea, to be awarded in 2026. The partnership reflects the Company’s commitment to the...

Collaboration leverages Converge Bio’s proprietary generative AI to design and optimize novel tri-specific antibodies for oncology needs AI-driven development strategy designed to significantly accelerate discovery timelines and enhance molecule quality for drug candidates targeting solid tumors REHOVOT, Israel and BOSTON, Mass., March 25, 2026 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing a next-generation immunotherapy platform designed to maximize anti-cancer potency while minimizing toxicity, today announced a collaboration with Converge Bio, a company known for its leading AI platform for drug discovery and development, to accelerate and enhance Purple Biotech’s next-generation tri-specific antibody platform...

Salt Lake City, UT, March 25, 2026 (GLOBE NEWSWIRE) — Recursion (Nasdaq: RXRX), a leading clinical-stage TechBio company decoding biology to radically improve lives, today announced that Vicki Goodman, M.D., will become Recursion’s Chief Medical Officer effective April 6, 2026 as David Mauro, M.D., Ph.D. transitions out of the role. As Recursion advances its pipeline and prepares for key clinical and regulatory milestones, which are consistent with previously communicated expectations, Dr. Goodman brings a rare and differentiated perspective of how to translate scientific promise into successful clinical programs. Her experience spans executive roles in biotech and large pharma, with particular expertise in oncology, as well as experience in clinical practice and as an FDA reviewer. “We are very excited to welcome Dr. Goodman to...

HOLMDEL, N.J., March 25, 2026 (GLOBE NEWSWIRE) — BIO-key International, Inc. (NASDAQ: BKYI), a global leader in Identity and Access Management (IAM) and biometric authentication technologies, will host its 2025 year-end investor call on Tuesday, March 31st at 10 a.m. ET with results issued prior the market opening. Mike DePasquale, Chairman & CEO and Cecilia Welch, CFO will lead the conference call and Q&A session.Call Details  Date / Time: Tuesday, March 31st at 10 a.m. ETCall Dial In #: 1-877-418-5460 U.S. or 1-412-717-9594 Int’lLive Webcast / Replay: Webcast & Replay Link – Available for 3 months.Audio Replay: 1-855-669-9658 U.S. or 1-412-317-0088 Int’l; code 4802902About BIO-key International, Inc. (www.BIO-key.com)BIO-key is revolutionizing authentication and cybersecurity with biometric-centric,...

25 March 2026 Announcement no. 3 Pharma Equity Group A/S – Annual Report 2025 Pharma Equity Group A/S – Annual Report 2025 – Highlights of the year Today, the Board of Directors of Pharma Equity Group A/S reviewed and approved the Company’s Annual Report for 2025, the key highlights of which are as follows:In 2025, Reponex Pharmaceuticals A/S obtained regulatory approval to initiate a pivotal Phase 2 trial of RNX-011 for the treatment of secondary bacterial peritonitis. In 2025, RNX-051 was further advanced through continued development work, further maturation of the formulation and continued dialogue with potential industrial partners. The Company is engaged in advanced and constructive discussions with potential partners regarding RNX-051, and, if progress continues as expected, these discussions are expected to be concluded...

MONTREAL, March 25, 2026 (GLOBE NEWSWIRE) — Volatus Aerospace Inc. (TSX: FLT) (OTCQB: TAKOF) (Frankfurt: ABB) (“Volatus” or the “Company”), a Canadian integrated aerospace and drone solutions provider delivering aerial intelligence, advanced training, and autonomous systems capabilities, today announced a strategic partnership with the University of Technology, Jamaica (“UTech, Jamaica”) to deliver advanced drone training and applied technology programs beginning in April 2026. The partnership expands Volatus Aerospace’s global training footprint and strengthens its presence in the Caribbean while supporting the development of skilled drone operators and applied technology specialists in regions increasingly adopting uncrewed aerial systems for disaster response, environmental monitoring, infrastructure management, and public safety...

TORONTO, March 25, 2026 (GLOBE NEWSWIRE) — Base Carbon Inc. (Cboe CA: BCBN) (OTCQX: BCBNF) with operations through its wholly-owned subsidiary, Base Carbon Capital Partners Corp. (“BCCPC”, together, with affiliates, “Base Carbon”, or the “Company”), is pleased to announce the issuance of 639,609 carbon credits from the Rwanda Cookstoves Project (the “Project”), marking the fourth issuance from the Project and the first issuance of carbon credits following the successful transition of the Project to Verra’s VM0050 methodology. Upon the purchase of required insurance, the carbon credits are expected to receive Carbon Offsetting and Reduction Scheme for International Aviation (“CORSIA”) eligible tagging, further strengthening the Project’s inventory of high-integrity, compliance-aligned carbon credits. The 639,609 carbon credits are...

CALGARY, Alberta, March 25, 2026 (GLOBE NEWSWIRE) — Marvel Biosciences Corp. (TSXV: MRVL | OTC: MBCOF), and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively “Marvel” or the “Company”), a drug discovery company developing novel, therapeutics for autism spectrum disorder and related conditions is pleased to announce that it has selected Novotech as the contract research organization (“CRO”) for the Company’s upcoming Phase I for its lead drug candidate MB-204. Novotech is an internationally recognized full service CRO based in Australia, that was awarded the 2025 Global Biotechnology Contract Research Organization Company of the Year by Frost & Sullivan in recognition of its innovation, client-focused delivery, and global impact. “Having previously worked with Novotech on multiple clinical programs, I am pleased...

BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) — Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases, today announced the appointment of Jane Wright-Mitchell, Pharm.D., J.D., as Chief Legal Officer, effective immediately. “Jane has worked with Vera Therapeutics previously as a strategic legal consultant and brings a depth and breadth of experience in supporting companies through regulatory approvals, commercialization, and intellectual property management,” said Marshall Fordyce, M.D., Founder and CEO of Vera Therapeutics. “As we near the potential launch of our first-in-class dual BAFF/APRIL inhibitor for patients with IgA nephropathy, Jane’s expertise will further strengthen our foundation for sustainable...